接受笔形扫描质子治疗的脑肿瘤患者脱发发生率及现有NTCP模型验证
该研究分析了2018至2022年间接受笔形扫描质子治疗的264例脑肿瘤患者,急性、晚期和永久性放射性脱发的发生率分别为61.8%、24.7%和14.4%。在独立队列中,LKB和MLR-NTCP模型对2级放射性脱发显示出良好的区分度(ROC-AUC 0.71–0.83),但校准不理想,可能源于训练与验证队列结局评估方式及临床治疗变量的差异。
要点
- 质子治疗后急性放射性脱发发生率为61.8%,晚期为24.7%,永久性为14.4%。
- LKB和MLR-NTCP模型对2级放射性脱发的ROC-AUC在0.71至0.83之间。
- 模型校准不理想,可能因训练与验证队列结局评估及变量差异所致。
核心结论
- 尽管NTCP模型在验证队列中对放射性脱发显示出合理的敏感性和特异性,但研究强调模型开发与验证所用队列之间的差异具有重要意义。
- 临床结局报告方式的差异不可避免地影响NTCP模型的验证,标准化的客观放射性脱发评分系统至关重要。
研究设计与样本
- 研究提取了2018年至2022年间接受扫描束质子治疗的脑肿瘤患者数据。
- 根据CTCAE 5.0评估急性、晚期和永久性放射性脱发事件。
- 基于头皮相对剂量-表面直方图计算已发表的Lyman-Kutcher-Burman(LKB)和多变量逻辑回归(MLR)模型。
- 从区分度和校准两方面评估模型的外部有效性。
主要发现
- 在分析的264例患者中,任何级别的急性放射性脱发(质子治疗完成后≤90天)发生率为61.8%。
- 晚期放射性脱发(>90天)发生率为24.7%。
- 永久性放射性脱发(持续>12个月)发生率为14.4%。
- 在独立队列中,LKB和MLR-NTCP模型对2级放射性脱发显示出良好的区分度(0.71≤ROC-AUC≤0.83)。
- 模型校准不理想,可能由于训练与验证队列之间结局评估不同以及两组临床和治疗相关变量的差异。
关键数值与推荐
- 急性放射性脱发定义为质子治疗完成后≤90天发生的任何级别事件。
- 晚期放射性脱发定义为质子治疗完成后>90天发生的事件。
- 永久性放射性脱发定义为持续超过12个月的事件。
- 放射性脱发分级依据CTCAE 5.0。
临床怎么用
- 原文未据此给出推荐。
局限性
- 模型校准不理想,可能由于训练与验证队列之间结局评估不同以及两组临床和治疗相关变量的差异。
- 临床结局报告方式的差异不可避免地影响NTCP模型的验证。
- 需要标准化的客观放射性脱发评分系统。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Radiation-induced alopecia (RIA) is one of the most frequent and upsetting cosmetic side effects after radiotherapy (RT) for brain cancer. We report the incidence of RIA in a cohort of brain tumours patients treated with Proton Therapy (PT) and externally validate published NTCP models of grade 2 (G2) RIA for their implementation in clinical practice. METHODS: Data for patients treated for brain tumours with scanning beam PT between 2018 and 2022 were extracted. Acute, late and permanent RIA events were evaluated according to CTCAE 5.0. Lyman-Kutcher-Burman (LKB) and multivariable logistic regression (MLR) published models were computed from the relative dose-surface histogram of the scalp. External validity of models was assessed in terms of discrimination and calibration. RESULTS: In the 264 patients analysed, rates of any grade acute (≤90 days after PT completion), late (>90 days) and permanent RIA (persisting for> 12 months) were 61.8 %, 24.7 % and 14.4 %, respectively. In our independent cohort, LKB- and MLR-NTCP showed a good discrimination for G2 RIA (0.71≤ROC-AUC≤0.83) while model calibration was unsatisfactory possibly due to a different outcome evaluation between training and validation cohorts, as well as differences in clinical and treatment related variables between the two groups. CONCLUSIONS: Despite the reasonable sensitivity and specificity of the NTCP models for RIA in the validation cohort, our study emphasizes the significance of differences between the cohorts utilized for model development and validation. Specifically, variations in the reporting of clinical outcomes inevitably jeopardize the validation of NTCP models. A standardize and objective RIA scoring system is essential.
引用
- Gaito S, Cella L, France A, et al. Incidence of alopecia in brain tumour patients treated with pencil scanning proton therapy and validation of existing NTCP models. Radiother Oncol. 2024. PMID: 39069083. doi:10.1016/j.radonc.2024.110462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。